[HTML][HTML] Phase 1b study of sintilimab plus anlotinib as first-line therapy in patients with advanced NSCLC
T Chu, R Zhong, H Zhong, BO Zhang, W Zhang… - Journal of Thoracic …, 2021 - Elsevier
Introduction Although the interaction between tumor immune microenvironment and
angiogenesis has been well established, evidence supporting the chemo-free combination …
angiogenesis has been well established, evidence supporting the chemo-free combination …
[HTML][HTML] Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: a randomized …
Y Yang, Z Wang, J Fang, Q Yu, B Han, S Cang… - Journal of Thoracic …, 2020 - Elsevier
Introduction Sintilimab, an anti–programmed death 1 antibody, plus pemetrexed and
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …
platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We …
[HTML][HTML] Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous NSCLC: results from a randomized, double-blind, phase …
C Zhou, L Wu, Y Fan, Z Wang, L Liu, G Chen… - Journal of Thoracic …, 2021 - Elsevier
Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes
platinum plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody …
platinum plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody …
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 …
L Zhang, Z Wang, J Fang, Q Yu, B Han, S Cang… - Lung Cancer, 2022 - Elsevier
Abstract Objectives In ORIENT-11, first-line sintilimab+ pemetrexed-platinum significantly
improved PFS compared with placebo+ pemetrexed-platinum in patients with advanced …
improved PFS compared with placebo+ pemetrexed-platinum in patients with advanced …
[HTML][HTML] Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic …
Y Yang, J Sun, Z Wang, J Fang, Q Yu, B Han… - Journal of Thoracic …, 2021 - Elsevier
Introduction Sintilimab plus chemotherapy significantly prolonged progression-free survival
(PFS) compared with chemotherapy alone in nonsquamous NSCLC in the ORIENT-11 …
(PFS) compared with chemotherapy alone in nonsquamous NSCLC in the ORIENT-11 …
Sintilimab for the treatment of non-small cell lung cancer
L Zhang, W Lin, F Tan, N Li, Q Xue, S Gao, Y Gao… - Biomarker …, 2022 - Springer
Abstract Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)
immunotherapy has dramatically changed the therapeutic landscape of inoperable non …
immunotherapy has dramatically changed the therapeutic landscape of inoperable non …
Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 …
Y Shi, L Wu, X Yu, P Xing, Y Wang… - Cancer …, 2022 - Wiley Online Library
Abstract Background Treatment options for Chinese patients with locally advanced or
metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line …
metastatic squamous‐cell non‐small‐cell lung cancer (sqNSCLC) after failure of first‐line …
Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non–small cell lung cancer: the ALTER 0303 phase 3 randomized …
B Han, K Li, Q Wang, L Zhang, J Shi, Z Wang… - JAMA …, 2018 - jamanetwork.com
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free …
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
H Liang, M Wang - Cancer Management and Research, 2019 - Taylor & Francis
In the latest years, some drugs have been approved by European Medicines Agency (EMA)
and/or the US Food and Drug Administration (FDA) for the treatment of patients with …
and/or the US Food and Drug Administration (FDA) for the treatment of patients with …
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
B Han, K Li, Y Zhao, B Li, Y Cheng, J Zhou, Y Lu… - British journal of …, 2018 - nature.com
Background: Anlotinib (AL3818) is a novel multitarget tyrosine kinase inhibitor, inhibiting
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …
tumour angiogenesis and proliferative signalling. The objective of this study was to assess …